Advertisement

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Peter Clark, MA, MD, FRCP: A Payer Perspective

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement

Nov

04

Today In Oncology

HER2-Positive Targeted Therapy Cardiovascular Risk: ACC Upcoming Journal Club

Upcoming ASCO AI in Oncology Webinar Turns Chatbot Printouts Into Better Patient Conversations

Hypofractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation Demonstrates Noninferior Locoregional Control

Neoadjuvant Niraparib Shows Activity in HRD-Positive Advanced Ovarian Cancer

A Fraction of the Fractions: SBRT Before Pancreatic Cancer Surgery

Advertisement

© 2026 HSP News Service, L.L.C.